Share This Page
LEVAMISOLE HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for levamisole hydrochloride and what is the scope of patent protection?
Levamisole hydrochloride
is the generic ingredient in one branded drug marketed by Janssen Pharma and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for LEVAMISOLE HYDROCHLORIDE
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 32 |
| DailyMed Link: | LEVAMISOLE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LEVAMISOLE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| International Centre for Diarrhoeal Disease Research, Bangladesh | PHASE2 |
| Cures Within Reach | PHASE2 |
| Institut de Recherche pour le Developpement | PHASE2 |
Medical Subject Heading (MeSH) Categories for LEVAMISOLE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for LEVAMISOLE HYDROCHLORIDE
US Patents and Regulatory Information for LEVAMISOLE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharma | ERGAMISOL | levamisole hydrochloride | TABLET;ORAL | 020035-001 | Jun 18, 1990 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEVAMISOLE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharma | ERGAMISOL | levamisole hydrochloride | TABLET;ORAL | 020035-001 | Jun 18, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Levamisole Hydrochloride Market Dynamics and Financial Trajectory
Levamisole hydrochloride is a mature, low-value pharmaceutical ingredient with no meaningful remaining branded-drug franchise in the United States. Its human oncology use declined after safety concerns and U.S. withdrawal of the branded product Ergamisol. Current legitimate demand is concentrated in selected veterinary, research, reference-standard, and international pharmaceutical markets. Public companies do not generally report levamisole hydrochloride revenue as a separate product line, making market-size and financial-trajectory estimates highly fragmented.
What is the current market status of levamisole hydrochloride?
Levamisole hydrochloride is the hydrochloride salt of levamisole, an immunomodulatory and anthelmintic compound. Its historical medical uses included:
- Adjuvant treatment of colon cancer with fluorouracil
- Treatment of helminth infections
- Veterinary deworming
- Experimental immunomodulatory applications
The U.S. human market has effectively ended. The FDA-approved oncology product, Ergamisol, was withdrawn from the U.S. market in 2000 after the risk-benefit profile deteriorated because of agranulocytosis and other serious adverse effects. The FDA listed the withdrawal in the Federal Register after the manufacturer requested withdrawal of the product’s approval.[1]
The active ingredient remains commercially relevant in narrower channels:
| Market channel | Current position | Financial relevance |
|---|---|---|
| U.S. human oncology | Withdrawn | Negligible |
| U.S. human anthelmintic use | No major approved branded franchise | Negligible |
| Veterinary medicines | Selective and jurisdiction-dependent | Low to moderate for specialized suppliers |
| International human medicines | Present in some markets, but limited | Low |
| Research and analytical standards | Active niche | Low |
| Illicit cocaine adulteration | Not a legitimate pharmaceutical market | No lawful revenue attribution |
Levamisole’s presence in cocaine supplies has created a public-health issue because exposure can cause agranulocytosis, vasculitis, skin necrosis, and neurologic complications. That illicit use does not represent pharmaceutical demand and should not be included in legitimate market forecasts.[2]
When did levamisole hydrochloride lose commercial exclusivity?
Levamisole hydrochloride lost meaningful commercial exclusivity decades ago. The compound was discovered and commercialized in the 1960s, placing the original composition-of-matter patent estate well beyond its ordinary U.S. patent term.
| Exclusivity category | Status |
|---|---|
| Original compound patents | Expired |
| Original human-use patents | Expired |
| Oncology combination claims | Expired or commercially obsolete |
| Formulation patents | No material active U.S. franchise identified |
| Method-of-use patents | Historical only in the major markets |
| Regulatory exclusivity | Expired |
| Biosimilar exclusivity | Not applicable |
The product therefore competes as an old small-molecule compound rather than as a protected pharmaceutical asset. Any current supplier generally competes on regulatory status, manufacturing quality, cost, geographic access, and customer qualification.
What patents protect levamisole hydrochloride?
No active U.S. patent estate appears to provide commercially meaningful protection for levamisole hydrochloride as a compound. The original patents associated with levamisole and its preparation were filed more than half a century ago and have expired.
Potential historical claim categories included:
- Levamisole composition claims
- Salt and stereochemical claims
- Chemical synthesis processes
- Anthelmintic methods
- Immunomodulatory methods
- Combination treatment with fluorouracil in colorectal cancer
Those claims do not create a current barrier to generic manufacture in the United States. A modern supplier could still face ordinary process patents, manufacturing know-how protections, regulatory documentation requirements, or jurisdiction-specific formulation claims. Those are commercial execution risks rather than a surviving core patent moat.
Are formulation patents important for levamisole hydrochloride?
Formulation patents have little current strategic value for the molecule. Levamisole hydrochloride is a conventional small molecule that can be formulated in tablets, oral solutions, veterinary boluses, and laboratory preparations. The original human product did not create a durable differentiated delivery platform.
A company developing a new dosage form could seek patents on:
- Modified-release tablets
- Taste-masked veterinary formulations
- Combination products
- Stabilized oral liquids
- Targeted delivery systems
- Specific manufacturing or particle-size controls
Such patents would protect a new product configuration, not levamisole hydrochloride itself. Commercial value would depend on regulatory approval and customer adoption, both of which are limited by the molecule’s safety history and narrow demand base.
What is the FDA regulatory status of levamisole hydrochloride?
The principal U.S. regulatory event was the withdrawal of Ergamisol, the branded human product. Levamisole had been used with fluorouracil as adjuvant therapy for colon cancer, but post-market safety concerns and changing oncology practice reduced its clinical role.
The U.S. regulatory position can be summarized as follows:
| FDA issue | Position |
|---|---|
| Branded human oncology product | Withdrawn |
| Current blockbuster or specialty-drug approval | None |
| Orange Book commercial relevance | Minimal |
| ANDA-driven generic market | No material active market identified |
| Veterinary use | Separate regulatory pathway and product status |
| Human relaunch opportunity | Low without a new clinical rationale |
Levamisole is not a biologic, so biosimilar regulation does not apply. A new human product would require an applicable FDA pathway, potentially including a new drug application if the proposed use, formulation, or clinical positioning did not fit an existing abbreviated pathway.
What is the Orange Book status of levamisole hydrochloride?
The Orange Book has little current commercial significance for levamisole hydrochloride. The withdrawal of the branded human product removed the principal U.S. reference-product franchise. Even if historical listings remain available in archival or regulatory records, they do not establish active market exclusivity.
A generic entrant would not face the type of Orange Book patent litigation associated with high-value oncology products such as Revlimid, Imbruvica, or Tagrisso. The key obstacle is regulatory and commercial viability, not patent expiry.
What companies manufacture or market levamisole hydrochloride?
The supplier base is fragmented. Levamisole hydrochloride has historically been produced or marketed by:
- Branded pharmaceutical companies, including Janssen in connection with Ergamisol
- Generic drug manufacturers
- Veterinary pharmaceutical companies
- Active pharmaceutical ingredient producers
- Laboratory reagent and reference-standard suppliers
- Contract manufacturers serving regional markets
Public disclosure is limited because levamisole usually represents a minor product within a broader portfolio. Companies generally do not report separate revenue, gross margin, customer concentration, or capacity utilization for the ingredient.
The market is therefore better analyzed through product registrations, import-export records, veterinary catalogs, procurement tenders, and API supplier databases than through public-company segment reporting.
How has the financial trajectory changed?
Levamisole hydrochloride followed a classic pharmaceutical lifecycle:
1960s to 1980s: broad clinical and veterinary commercialization
The molecule gained acceptance as an anthelmintic and immunomodulator. Veterinary applications supported recurring demand, while human use created higher-value branded sales. Pricing was stronger when the compound was sold as a branded prescription medicine.
1990s: oncology positioning followed by erosion
The FDA-approved use with fluorouracil created a specialized oncology market. The commercial opportunity remained limited compared with modern cancer drugs because levamisole was an adjunct rather than a high-priced targeted therapy.
Safety concerns, competing treatment approaches, and the emergence of more effective oncology regimens weakened the product’s position. Agranulocytosis became a central commercial liability.[1][3]
2000 onward: U.S. human withdrawal
The U.S. withdrawal of Ergamisol removed the most visible branded-market opportunity. Revenue shifted away from branded human pharmaceuticals toward low-margin generic, veterinary, and international channels.
Current period: fragmented residual demand
Current financial value is concentrated in small, price-sensitive niches. The product does not support a conventional high-growth pharmaceutical investment thesis. Revenue can remain stable for individual suppliers if they hold qualified manufacturing capacity or serve regulated veterinary and laboratory customers, but industrywide growth is constrained.
| Financial driver | Direction |
|---|---|
| U.S. branded revenue | Collapsed |
| Human oncology demand | Structurally reduced |
| Veterinary demand | Selective, relatively durable |
| API pricing | Low and competitive |
| Research-standard demand | Stable but very small |
| Regulatory overhead | High relative to product value |
| Margin potential | Better for qualified niche supply than bulk commodity supply |
| Growth outlook | Flat to declining |
No reliable public source provides a consolidated global revenue figure for levamisole hydrochloride. Product-level financial data are generally embedded in broader API, veterinary, or generic portfolios.
What generic entry risks exist for levamisole hydrochloride?
Generic entry risk is not the principal commercial issue because the compound is already generic and largely unprotected. The relevant risks are:
- Regulatory withdrawal or nonrenewal in a target market.
- Pharmacovigilance obligations arising from agranulocytosis and vasculitic reactions.
- Limited physician demand in human medicine.
- Competition from established low-cost suppliers.
- Veterinary product restrictions or changes in animal-health policy.
- Customer reluctance to qualify a new API supplier for a low-volume product.
- Quality-control requirements for impurities, residual solvents, polymorphism, and assay consistency.
A new entrant would likely need a contracted customer or a defined regional market before investing in dedicated capacity. Manufacturing for speculative inventory would carry high working-capital and obsolescence risk.
Which companies are challenging the levamisole hydrochloride market?
There is no prominent current Paragraph IV campaign targeting a high-value levamisole product. The market lacks the revenue concentration that normally attracts organized patent challenges.
Competitive pressure instead comes from:
- Generic API manufacturers in India and China
- Regional veterinary-drug producers
- International suppliers serving legacy human indications
- Laboratory and reference-standard companies
- Contract manufacturers with multiproduct facilities
Competition is primarily price-based. Supplier differentiation depends on regulatory files, inspection history, consistency of supply, analytical documentation, and ability to support customer audits.
What patent litigation affects levamisole hydrochloride?
No major active U.S. patent litigation is associated with the core levamisole hydrochloride market. Historical disputes, if any, would concern manufacturing, formulation, or commercial distribution rather than surviving compound patents.
The absence of litigation reflects the market’s economics. Levamisole hydrochloride has limited branded revenue, expired core patents, and no current U.S. blockbuster product. Litigation costs would be difficult to justify against the expected value of the market.
Are there licensing deals for levamisole hydrochloride?
No major current licensing transaction is publicly associated with levamisole hydrochloride. Historical commercialization involved branded pharmaceutical distribution and product marketing arrangements, but the molecule does not have an active platform or specialty indication that would normally generate substantial licensing activity.
Any current agreement is more likely to be:
- A regional veterinary distribution contract
- An API supply agreement
- A contract manufacturing arrangement
- A reference-standard distribution relationship
- A legacy marketing authorization transfer
These agreements are unlikely to be material to the financial statements of diversified pharmaceutical companies.
How does levamisole hydrochloride compare with competing anthelmintics?
Levamisole competes with newer or better-tolerated anthelmintics in veterinary and parasitology markets. Its competitive position varies by species, parasite, resistance pattern, jurisdiction, and product formulation.
| Attribute | Levamisole hydrochloride | Benzimidazoles | Macrocyclic lactones |
|---|---|---|---|
| Core use | Anthelmintic | Broad anthelmintic use | Broad veterinary parasite control |
| Patent status | Expired | Mostly mature | Product-specific, many mature |
| Safety perception | Constrained by toxicity history | Generally established, product-dependent | Product- and species-dependent |
| Pricing | Low | Low to moderate | Moderate to high in branded products |
| Human oncology relevance | Historical | None comparable | None comparable |
| Growth profile | Flat or declining | Mature | More commercially durable |
Levamisole may retain value where local resistance patterns, legacy protocols, or cost favor its use. Its broader market position remains weaker than products with better safety, longer duration, or more convenient dosing.
What is the commercial outlook for levamisole hydrochloride?
The base case is a stable but shrinking mature-ingredient market. The most defensible revenue opportunities are in:
- Veterinary products in markets where levamisole remains registered
- API supply to established regional manufacturers
- Laboratory reference materials
- Specialized international products
- Contract manufacturing for low-volume formulations
A meaningful rebound would require a new approved indication, a differentiated formulation, or a major change in parasite-control practice. None is evident from the molecule’s current regulatory and commercial position.
Key Takeaways
- Levamisole hydrochloride is a mature, off-patent small molecule.
- The U.S. human branded market ended with the withdrawal of Ergamisol in 2000.
- No meaningful active Orange Book or patent-exclusivity barrier supports a premium franchise.
- Biosimilar risk is irrelevant because levamisole is not a biologic.
- Current lawful demand is concentrated in veterinary, international, research, and reference-standard channels.
- Public companies generally do not disclose levamisole-specific revenue.
- Financial growth is unlikely; niche suppliers may generate stable but limited returns.
- The main risks are regulatory, toxicological, quality-related, and demand-related rather than patent-related.
- No major current Paragraph IV campaign, licensing transaction, or U.S. patent litigation is apparent for the core product.
FAQs
Is levamisole hydrochloride still used in humans?
Yes, it may remain available in selected international markets, but its U.S. human oncology use was withdrawn and its clinical role is limited by serious safety concerns.
Is levamisole hydrochloride a generic drug?
It is an off-patent small-molecule active ingredient. Whether a specific finished product is legally marketed as a generic depends on the jurisdiction, dosage form, indication, and regulatory authorization.
Can levamisole hydrochloride be relaunched for cancer treatment?
A relaunch would require a new regulatory strategy and clinical evidence. The historical colorectal-cancer use does not provide current U.S. exclusivity or an automatic approval pathway.
Does levamisole hydrochloride have veterinary growth potential?
Growth is limited but possible in selected regions and species. Demand depends on local registration, parasite resistance, competing products, and veterinary prescribing practices.
Is levamisole hydrochloride associated with supply-chain risk?
Supply risk is generally more relevant than patent risk. Low volumes, limited qualified suppliers, regulatory audits, and safety-related controls can make procurement vulnerable even when the API itself is widely known.
References
-
U.S. Food and Drug Administration. (2000). Withdrawal of approval of new drug application for levamisole hydrochloride tablets. Federal Register.
-
National Institute on Drug Abuse. (2020). Rising use of levamisole as a cocaine adulterant. National Institutes of Health.
-
National Cancer Institute. (n.d.). Levamisole hydrochloride. Drug dictionary and cancer treatment information. National Institutes of Health.
More… ↓
